{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T06:09:09Z","timestamp":1778998149810,"version":"3.51.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There is an urgent need to identify differentiating and disease-monitoring biomarkers of schizophrenia, bipolar disorders (BD), and major depressive disorders (MDD) to improve treatment and management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We recruited 54 first-episode schizophrenia (FES) patients, 52 BD patients, 35 MDD patients, and 54 healthy controls from inpatient and outpatient clinics. <jats:italic>\u03b1<\/jats:italic>-Melanocyte Stimulating Hormone (<jats:italic>\u03b1<\/jats:italic>-MSH), <jats:italic>\u03b2<\/jats:italic>-endorphin, neurotensin, orexin-A, oxytocin, and substance P were investigated using quantitative multiplex assay method. Psychotic symptoms were measured using the Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS), manic symptoms using the Young Mania Rating Scale (YMRS), and depressive symptoms using 17 item-Hamilton Depression Rating Scale (HAMD). We additionally measured cognitive function by using a battery of tests given to all participants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>\u03b1<\/jats:italic>-MSH, neurotensin, orexin-A, oxytocin, and substance P were decreased in the three patient groups compared with controls. Neurotensin outperformed all biomarkers in differentiating patient groups from controls. There were no significant differences for 6 neuropeptides in their ability to differentiate between the three patient groups. Higher neurotensin was associated with better executive function across the entire sample. Lower oxytocin and higher substance p were associated with more psychotic symptoms in FES and BD groups. <jats:italic>\u03b2<\/jats:italic>-endorphin was associated with early morning wakening symptom in all three patient groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our research shows decreased circulating neuropeptides have the potential to differentiate severe mental illnesses from controls. These neuropeptides are promising treatment targets for improving clinical symptoms and cognitive function in FES, BD, and MDD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1180720","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T06:00:11Z","timestamp":1684476011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Decreased plasma neuropeptides in first-episode schizophrenia, bipolar disorder, major depressive disorder: associations with clinical symptoms and cognitive function"],"prefix":"10.3389","volume":"14","author":[{"given":"Hua","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liansheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangdong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanjun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Coid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/NDT.S96649","article-title":"Global economic burden of schizophrenia: a systematic review","volume":"12","author":"Chong","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiat"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fpsyt.2019.00052","article-title":"Common and specific functional activity features in schizophrenia, major depressive disorder, and bipolar disorder","volume":"10","author":"Yang","year":"2019","journal-title":"Front Psych"},{"key":"ref4","first-page":"4","article-title":"Integrated pathophysiology of schizophrenia, major depression, and bipolar disorder as monoamine axon disorder.","volume-title":"Front Biosci (Schol Ed)","author":"Nakamura","year":"2022"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"784370","DOI":"10.3389\/fpsyt.2021.784370","article-title":"Treatment of symptom clusters in schizophrenia, bipolar disorder and major depressive disorder with the dopamine D3\/D2 preferring partial agonist Cariprazine","volume":"12","author":"Batinic","year":"2021","journal-title":"Front Psych"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1093\/schbul\/sbw058","article-title":"Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and Meta-analysis","volume":"42","author":"Zhang","year":"2016","journal-title":"Schizophr Bull"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.31887\/DCNS.2002.4.1\/bbondy","article-title":"Pathophysiology of depression and mechanisms of treatment","volume":"4","author":"Brigitta","year":"2002","journal-title":"Dialogues Clin Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/ijms22042146","article-title":"Oxytocin in schizophrenia: pathophysiology and implications for future treatment","volume":"22","author":"Goh","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev.pharmtox.41.1.237","article-title":"Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence","volume":"41","author":"Carlsson","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1176\/ajp.152.11.1635","article-title":"Relapse and impairment in bipolar disorder","volume":"152","author":"Gitlin","year":"1995","journal-title":"Am J Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"E8472","DOI":"10.1073\/pnas.1617824113","article-title":"Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide","volume":"113","author":"Barde","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/nrd3702","article-title":"Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?","volume":"11","author":"Griebel","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1399-5618.2007.00385.x","article-title":"Effects of treatment latency on response to maintenance treatment in manic-depressive disorders","volume":"9","author":"Baldessarini","year":"2007","journal-title":"Bipolar Disord"},{"key":"ref14","first-page":"327","article-title":"Involvement of neuropeptide Systems in Schizophrenia: human studies","volume-title":"International review of neurobiology","author":"C\u00e1ceda","year":"2007"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"152114","DOI":"10.1016\/j.comppsych.2019.152114","article-title":"Plasma neuropeptides as circulating biomarkers of multifactorial schizophrenia","volume":"94","author":"Ni","year":"2019","journal-title":"Compr Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fncir.2018.00106","article-title":"Neuropeptide and small transmitter coexistence: fundamental studies and relevance to mental illness","volume":"12","author":"H\u00f6kfelt","year":"2018","journal-title":"Front Neural Circuits"},{"key":"ref17","volume-title":"Neuropeptides. In: Molecular neuropharmacology: A Foundation for Clinical Neuroscience, 3Edn","author":"Nestler","year":"2015"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/10298420290031432","article-title":"Neuropeptides involved in the pathophysiology of schizophrenia and major depression","volume":"4","author":"de Wied","year":"2002","journal-title":"Neurotox Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s12031-014-0404-6","article-title":"Association of Neurotensin receptor 1 gene polymorphisms with processing speed in healthy Chinese-Han subjects","volume":"54","author":"Wang","year":"2014","journal-title":"J Molecul Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2174\/1871527311312050010","article-title":"Neuropeptide systems and schizophrenia","volume":"12","author":"LaCrosse","year":"2013","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref21","first-page":"187","article-title":"Vasopressin\u2013oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls","volume":"10","author":"Beckmann","year":"1985","journal-title":"Netherlands: Elsevier Science"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0920-9964(94)90021-3","article-title":"Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication","volume":"11","author":"Glovinsky","year":"1994","journal-title":"Schizophr Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.schres.2011.07.027","article-title":"Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia","volume":"132","author":"Pedersen","year":"2011","journal-title":"Schizophr Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/HRP.0b013e3182a75b7d","article-title":"The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings","volume":"21","author":"Cochran","year":"2013","journal-title":"Harv Rev Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.npep.2013.10.014","article-title":"Role of neuropeptides in anxiety, stress, and depression: from animals to humans","volume":"47","author":"Kormos","year":"2013","journal-title":"Neuropeptides"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.neuropharm.2010.01.006","article-title":"Involvement of alpha-MSH in the social isolation induced anxiety- and depression-like behaviors in rat","volume":"58","author":"Kokare","year":"2010","journal-title":"Neuropharmacology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/ijms22010338","article-title":"Roles of \u03b2-endorphin in stress, behavior, neuroinflammation, and brain energy metabolism","volume":"22","author":"Pilozzi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.npep.2009.06.004","article-title":"The role of beta-endorphin in the pathophysiology of major depression","volume":"43","author":"Hegadoren","year":"2009","journal-title":"Neuropeptides"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1749-6632.1988.tb42113.x","article-title":"Neuropeptides, dopamine, and schizophrenia","volume":"537","author":"Nemeroff","year":"1988","journal-title":"Ann N Y Acad Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease","volume":"17","author":"Simr\u00e9n","year":"2021","journal-title":"Alzheimers Dement"},{"key":"ref31","volume-title":"Manual for the Wechsler adult intelligence scale, Revised.","author":"Wechsler","year":"1981"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/13803395.2018.1529229","article-title":"Assessment of neuropsychological performance in Mexico City youth using the Cambridge neuropsychological test automated battery (CANTAB)","volume":"41","author":"Green","year":"2019","journal-title":"J Clin Exp Neuropsychol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1038\/tp.2015.91","article-title":"Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset","volume":"5","author":"Chan","year":"2015","journal-title":"Transl Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1017\/S0033291709990651","article-title":"Combining dimensional and categorical representation of psychosis: the way forward for DSM-V and ICD-11?","volume":"39","author":"Demjaha","year":"2009","journal-title":"Psychol Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1176\/ajp.154.7.1019","article-title":"CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder","volume":"154","author":"Sharma","year":"1997","journal-title":"Am J Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1176\/ajp.139.9.1122","article-title":"Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment","volume":"139","author":"Widerl\u00f6v","year":"1982","journal-title":"Am J Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fgene.2013.00297","article-title":"G protein-linked signaling pathways in bipolar and major depressive disorders","volume":"4","author":"Tomita","year":"2013","journal-title":"Front Genet"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.molbrainres.2004.06.038","article-title":"Gene expression profiles highlight adaptive brain mechanisms in corticotropin releasing factor overexpressing mice","volume":"129","author":"Peeters","year":"2004","journal-title":"Brain Res Mol Brain Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"949","DOI":"10.5665\/sleep.1958","article-title":"Altered sleep and affect in the neurotensin receptor 1 knockout mouse","volume":"35","author":"Fitzpatrick","year":"2012","journal-title":"Sleep"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3389\/fpsyt.2019.00253","article-title":"The relationship between cognitive dysfunction and symptom dimensions across schizophrenia, bipolar disorder, and major depressive disorder","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Psych"},{"key":"ref41","first-page":"627","article-title":"Future of neuropeptides in biological psychiatry and emotional psychopharmacology: goals and strategies","volume-title":"Textbook of biological psychiatry","author":"Panksepp","year":"2004"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e17365","DOI":"10.1371\/journal.pone.0017365","article-title":"Neurotensin receptor 1 gene (NTSR1) polymorphism is associated with working memory","volume":"6","author":"Li","year":"2011","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1523\/JNEUROSCI.3579-04.2005","article-title":"Neurotensin activates GABAergic interneurons in the prefrontal cortex","volume":"25","author":"Petrie","year":"2005","journal-title":"J Neurosci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1017\/S1355617798455073","article-title":"A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge neuropsychological test automated battery","volume":"4","author":"Robbins","year":"1998","journal-title":"J Int Neuropsychol Soc"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.schres.2012.06.016","article-title":"Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia","volume":"139","author":"Sasayama","year":"2012","journal-title":"Schizophr Res"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.psychres.2008.06.034","article-title":"Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment","volume":"169","author":"Ozsoy","year":"2009","journal-title":"Psychiatry Res"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12576-012-0232-9","article-title":"Oxytocin: a therapeutic target for mental disorders","volume":"62","author":"Matsuzaki","year":"2012","journal-title":"J Physiol Sci"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1034\/j.1600-0447.2000.102005386.x","article-title":"Prolactin and beta-endorphin serum elevations after ECT in manic patients","volume":"102","author":"Chaudhry","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecam\/nep132","article-title":"Endogenous opiates in the nucleus tractus solitarius mediate electroacupuncture-induced sleep activities in rats","volume":"2011","author":"Cheng","year":"2011","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.2147\/NDT.S209023","article-title":"Reduced plasma orexin-a levels in patients with bipolar disorder","volume":"15","author":"Tsuchimine","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/med.21326","article-title":"The hypocretin\/orexin system: an increasingly important role in neuropsychiatry","volume":"35","author":"Chen","year":"2015","journal-title":"Med Res Rev"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3389\/fpsyt.2019.00834","article-title":"The role of proopiomelanocortin and \u03b1-melanocyte-stimulating hormone in the metabolic syndrome in psychiatric disorders: a narrative Mini-review","volume":"10","author":"Raue","year":"2019","journal-title":"Front Psych"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1113\/jphysiol.2007.148965","article-title":"Substance P depolarizes striatal projection neurons and facilitates their glutamatergic inputs","volume":"586","author":"Blomeley","year":"2008","journal-title":"J Physiol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0006-8993(83)90095-1","article-title":"Peptides, the limbic lobe and schizophrenia","volume":"288","author":"Roberts","year":"1983","journal-title":"Brain Res"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/mp.2016.90","article-title":"Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review","volume":"21","author":"Tr\u00e9panier","year":"2016","journal-title":"Mol Psychiatry"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/npr2.12304","article-title":"Plasma neuropeptide levels in patients with schizophrenia, bipolar disorder, or major depressive disorder and healthy controls: a multiplex immunoassay study","volume":"43","author":"Hidese","year":"2023","journal-title":"Neuropsychopharmacol Rep"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"e17213","DOI":"10.1371\/journal.pone.0017213","article-title":"Age-related differences in plasma proteins: how plasma proteins change from neonates to adults","volume":"6","author":"Ignjatovic","year":"2011","journal-title":"PLoS One"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S1607-551X(08)70003-2","article-title":"Neuropeptide Y gene polymorphism and plasma neuropeptide Y level in febrile seizure patients in Taiwan","volume":"23","author":"Lin","year":"2007","journal-title":"Kaohsiung J Med Sci"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/jpm.2008.9690","article-title":"Study design, precision, and validity in observational studies","volume":"12","author":"Carlson","year":"2009","journal-title":"J Palliat Med"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1180720\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T06:00:21Z","timestamp":1684476021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1180720\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":59,"alternative-id":["10.3389\/fpsyt.2023.1180720"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1180720","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"article-number":"1180720"}}